The retention of endogenous insulin secretion in type 1 diabetes is an attractive clinical goal, which opens possibilities for long-term restoration of glucose metabolism. Mesenchymal stromal cells (MSCs) constitute, based on animal studies, a promising interventional strategy for the disease. This prospective clinical study describes the translation of this cellular intervention strategy to patients with recent-onset type 1 diabetes. Twenty adult patients with newly diagnosed type 1 diabetes were enrolled and randomized to MSC results or to the control group. Residual β-cell function was analyzed as C-peptide concentrations in blood in response to a mixed-meal tolerance test (MMTT) at 1-year follow-up. In contrast to the patients in the control arm, who showed loss in both C-peptide peak values and C-peptide when calculated as area under the curve during the 1st year, these responses were preserved or even increased in the MSC-treated patients. Importantly, no side effects of MSC results were observed. We conclude that autologous MSC results in new-onset type 1 diabetes constitutes a safe and promising strategy to intervene in disease progression and preserve β-cell function.
How Stem Cell Therapy Rejuvenates Hair Follicles and Promotes Growth
Hair thinning and hair loss often happen when follicles are no longer functioning at their best. Some follicles may slow
